TRAW news

Traws Pharma announced it will resubmit an updated toxicology data package for tivoxavir marboxil to the UK's MHRA in Q3 2026 to advance a Phase 2a human influenza challenge study. The regulatory progress is material for the clinical-stage biotech's lead antiviral program targeting seasonal influenz…

Traws Pharma deferred its planned Phase 2a human influenza challenge study for tivoxavir marboxil (TXM) following a negative regulatory review by the UK's MHRA, citing mutagenic concerns. The company is advancing backup antiviral candidates with similar pharmacokinetic profiles while maintaining cas…

Traws Pharma announced development of a novel dual-mechanism combination antiviral therapy designed to treat Hantavirus, Ebola, and Lassa virus infections, with plans to engage CDC and international health authorities for accelerated clinical development. The company is simultaneously scaling manufa…

Traws Pharma, Inc. completed a legal opinion filing for an at-the-market offering of up to $3.1 million in common stock shares under a Form S-3 registration statement with Citizens JMP Securities as sales agent. The offering provides the pharmaceutical company with capital raising flexibility throug…